Chief Executive Officer
CurrentiFAST is developing a game-changing, rapid antimicrobial susceptibility test, that will enable every patient with a bacterial infections to receive the right antibiotic, on time, every time. Currently these tests take 48-72 hours, but ours is 10x faster, cheaper and involves less tedious manual labour. This is a $4bn market and we expect to bring our product to market at the end of next year....